Compare · ABSI vs ICLR
ABSI vs ICLR
Side-by-side comparison of Absci Corporation (ABSI) and ICON plc (ICLR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABSI and ICLR operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- ICLR is the larger of the two at $12.93B, about 7.8x ABSI ($1.65B).
- ICLR has been more active in the news (19 items in the past 4 weeks vs 6 for ABSI).
- ICLR has more recent analyst coverage (25 ratings vs 21 for ABSI).
- Company
- Absci Corporation
- ICON plc
- Price
- $9.64+8.80%
- $169.03-2.64%
- Market cap
- $1.65B
- $12.93B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 1998
- News (4w)
- 6
- 19
- Recent ratings
- 21
- 25
Absci Corporation
Absci Corporation, an AI-powered synthetic biology company, offers biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. The company was founded in 2011 and is headquartered in Vancouver, Washington.
ICON plc
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including product development planning, strategic consulting, study protocol preparation, clinical pharmacology, pharmacokinetic and pharmacodynamic analysis, site feasibility, patient recruitment and retention, digital patient and site, project management, clinical operations/monitoring, patient centric monitoring, data management, and adaptive and virtual trial services. The company's clinical development services also comprise medical imaging, biostatistics, medical affairs, pharmacovigilance, strategic regulatory, electronic endpoint adjudication, medical writing and publishing, interactive response technologies, functional solutions, strategic resourcing central laboratory, bioanalytical laboratory, biomarket development, strategy and analytics, late phase research, patient centered science, and medical device and diagnostics research services, as well as access, commercialization, and communication services, and research trials for us government agencies. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON has an agreement with Evergreen Therapeutics, Inc. to conduct Phase II clinical trial for COVID-19 drug candidate. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
Latest ABSI
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- SEC Form 10-Q filed by Absci Corporation
- Absci Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results
- SEC Form 4 filed by CMO, Head of R&D Somaratne Ransi Mudalinayake
- SEC Form 3 filed by new insider Somaratne Ransi Mudalinayake
- As AI Rewrites Drug Discovery, This Bio-Native AI Company Just Joined the Russell 3000E, and Reports Earnings July 22
- Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026
- Director Szela Mary T bought $148,866 worth of shares (12,900 units at $11.54), increasing direct ownership by 154% to 21,300 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
Latest ICLR
- SEC Form 6-K filed by ICON plc
- SEC Form 6-K filed by ICON plc
- Amendment: SEC Form SCHEDULE 13G/A filed by ICON plc
- Director O'Neill Julie converted options into 1,732 units of Ordinary Shares and sold $150,326 worth of Ordinary Shares (915 units at $164.29), increasing direct ownership by 30% to 3,515 units (SEC Form 4) to satisfy tax liability
- Director Whitaker Anne Clem converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29) (SEC Form 4) to satisfy tax liability
- Director Murray Ciaran sold $439,803 worth of Ordinary Shares (2,677 units at $164.29) and converted options into 2,677 units of Ordinary Shares (SEC Form 4) (for tax liability)
- Director Murphy Ronan Martin converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 30% to 3,847 units (SEC Form 4) (tax withholding)
- Director Mccague Eugene Pacelli converted options into 1,732 units of Ordinary Shares and sold $138,168 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 31% to 3,811 units (SEC Form 4) (tax liability)
- Director Grais Linda converted options into 1,732 units of Ordinary Shares and sold $138,169 worth of Ordinary Shares (841 units at $164.29), increasing direct ownership by 17% to 6,162 units (SEC Form 4) (for withholding tax)
- SEC Form 4 filed by Chief Accounting Officer Lyons Emer